Press release: dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study

Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study study met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with dupixent than placebo dupixent is the first medicine to show significant steroid-sparing effect in this debilitating and life-threatening disease if approved, dupixent would be the first and only targeted medicine to treat bp in the u.s. and european union paris and tarrytown, ny, september 11, 2024. a dupixent (dupilumab) pivotal study (adept) in bullous pemphigoid (bp) met the primary and all key secondary endpoints evaluating its investigational use in adults with moderate-to-severe disease.
REGN Ratings Summary
REGN Quant Ranking